Search | IOVS | ARVO Journals

View

Showing 1 – 18 of 18

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2020

Limitations of Lesion Perimeter for Measurement of Geographic Atrophy Progression

Alice Blaj; Lewis Amber; Kevin Kerr; Werner Schmidt; Francisco J. Lopez

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2987. doi:

ARVO Annual Meeting Abstract July 2019

Phase 2b Study of Brimonidine DDS: Potential Novel Treatment for Geographic Atrophy

William R Freeman; Francesco Bandello; Eric H Souied; Robyn H Guymer; Sunir Garg; Fred Kuanfu Chen; Ryan M Rich; Frank G Holz; Yan Li; Kevin Kerr; Francisco J. Lopez

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):971. doi:

ARVO Annual Meeting Abstract July 2018

A Novel Iridocorneal Angle Measurement Technique: Assessment of Inter- and Intra-Scorer Variability

Ashley Nguyen; Quoc Ho; Francisco J. Lopez; Kevin Kerr; Susan Schneider; Jingyuan Yang; Margot L Goodkin; Michelle Y. Chen

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1699. doi:

ARVO Annual Meeting Abstract July 2018

Identification of Novel Biomarkers in Geographic Atrophy using Wide Spectrum Multiplexing

Kameran Lashkari; Gianna C Teague; Ursula Beattie; Megan McLaughlin; Francisco J. Lopez

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2417. doi:

ARVO Annual Meeting Abstract July 2018

Identification of Key Vitreous Biomarkers in Diabetic Macular Edema Associated with Proliferative Diabetic Retinopathy

Gianna C Teague; Namrata Nandakumar; Francisco J. Lopez; Kameran Lashkari

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4834. doi:

ARVO Annual Meeting Abstract July 2018

Diabetic Macular Ischemia: Angio-OCT measurement compared to fluorescein angiography

JOSE FRANCISCO VALDEZ VALDEZ LOPEZ

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2799. doi:

ARVO Annual Meeting Abstract June 2017

Brimonidine Drug Delivery System (DDS) Generation 1 in patients with geographic atrophy: Post-hoc analysis of a phase 2 study

Baruch D Kuppermann; Sunil S Patel; David S Boyer; Albert J Augustin; William R Freeman; Thomas Kim; Kevin Kerr; Francisco J Lopez; Susan Schneider

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1924. doi:

ARVO Annual Meeting Abstract June 2017

A systematic approach to statistical evaluation of geographic atrophy clinical studies

Thomas Kim; Alan Mitchell; Jeen Liu; Kevin Kerr; Francisco J Lopez; Susan Schneider

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2341. doi:

ARVO Annual Meeting Abstract June 2017

Comparison of Three Baseline Measures to Predict Geographic Atrophy Progression Rate in Clinical Studies

Quoc Ho; Mia Mackowski; Kevin Kerr; Francisco J Lopez; Susan Schneider

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2343. doi:

ARVO Annual Meeting Abstract June 2017

Analysis of Vitreous Biomarkers in Proliferative Diabetic Retinopathy and Macular Edema

Namrata Nandakumar; Francisco J Lopez; Gianna C Teague; Kameran Lashkari

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5807. doi:

ARVO Annual Meeting Abstract September 2016

COMPLEMENT FACTOR I BIOACTIVITY: A POTENTIAL BIOMARKER FOR ANTI-AMYLOID BETA TREATMENT IN AGE-RELATED MACULAR DEGENERATION/GEOGRAPHIC ATROPHY

Francisco J Lopez; Hong Chen; Yong-Qing Lin; Sanjay Kumar; Megan M McLaughlin

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2129. doi:

ARVO Annual Meeting Abstract September 2016

Are Systemic Levels of Amyloid β Altered in Patients with Geographic Atrophy?

Kameran Lashkari; Francisco J Lopez; Gianna C Teague; Sanjay Kumar; Megan M McLaughlin

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi:

ARVO Annual Meeting Abstract September 2016

Evaluation of Vitreous Factor in Proliferative Diabetic Retinopathy

Namrata Nandakumar; Gianna C Teague; Francisco J Lopez; Walter Johnson; Kameran Lashkari

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5452. doi:

ARVO Annual Meeting Abstract June 2015

Baseline Characteristics of BAM114341 population, a Phase II study in geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD)

Shawn Patrick Shearn; Mike Fries; John I Wurzelmann; Francisco J Lopez; Michael R Schwartz; Rabia Ozden; Baruch Kuppermann; BAM114341 Study Group

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2840. doi:

ARVO Annual Meeting Abstract June 2015

SNPs Associated with Complement Factor I Do Not Predict 4-month Lesion Growth Rate in Geographic Atrophy

John I Wurzelmann; Francisco J Lopez; Mike Fries; Shawn Patrick Shearn; Michael R Schwartz; Astrid Yeo; Lingkang Huang; Amitha Domalpally; Ronald P Danis; Rabia Ozden; BAM114341

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2850. doi:

ARVO Annual Meeting Abstract June 2015

IL-18 immunotherapy for neovascular AMD; Tolerability and efficacy in non-human primates

Matthew Campbell; Peter S Adamson; Francisco J Lopez; Edit Kurali; Peter Humphries; Sarah Doyle

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4803. doi:

ARVO Annual Meeting Abstract June 2015

A Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin , GSK2126458, Inhibits Laser-Induced Choroidal Neovascularization

Yu Sun; Jie Ma; Gianna C Teague; Francisco J Lopez; Peter S Adamson; Edit Kurali; Kameran Lashkari

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2364. doi:

ARVO Annual Meeting Abstract June 2015

IL-18 promotes wound healing and has anti-angiogenic properties in the eye

Sarah Doyle; Peter S Adamson; Francisco J Lopez; Peter Humphries; Matthew Campbell

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2462. doi:

Advertisement